Clinical trials: Metformin
Type 2 Diabetes Mellitus
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin…
- Trial name
- NCT02435277
- Testing
- Low Metformin, Mid Metformin, High Metformin
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- NuSirt Biopharma
Diabetes Mellitus
Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT01890122
- Testing
- Alogliptin, Metformin HCl, Alogliptin and Metformin Fixed-Dose Combination (FDC)
- Where
- 45 sites in China, Malaysia and 2 more
- Volunteers
- 647 people
- Sponsor
- Takeda
Healthy Volunteers
Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics
The purpose of this study is to learn about a drug-drug interaction. When two medications are taken together at the same time, one medication may change the activity of the other medication in the body - this is called a…
- Trial name
- NCT03655301
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Metformin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and…
- Trial name
- NCT02121509
- Testing
- Linagliptin, Linagliptin/Metformin ER FDC, Metformin ER
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diffuse Large B-Cell Lymphoma
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
Newly diagnosed histologically confirmed c-myc+ de novo DLBCL. Metformin 500 mg daily x 1 week, then 500 mg twice daily (BID) x 2 weeks, then 850 mg twice daily until 1 month after last cycle of chemo-immunotherapy.
- Trial name
- DLBCL (NCT02815397)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rush University Medical Center
Acute Lymphoblastic Leukemia, Hyperglycemia
Metformin and Transient Hyperglycemia
The purpose of this study is to determine whether metformin is an effective adjunctive treatment for transient hyperglycemia in patients with acute lymphoblastic leukemia (ALL) undergoing induction chemotherapy
- Conditions
- Acute Lymphoblastic Leukemia, Hyperglycemia, Insulin Resistance, Diabetes Mellitus
- Trial name
- NCT01486043
- Testing
- Metformin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital Los Angeles
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who…
- Trial name
- NCT01278160
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Novo Nordisk A/S
Gestational Diabetes
Metformin Versus Insulin in Gestational Diabetes
Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes.
- Trial name
- NCT01240785
- Testing
- metformin, insulin
- Volunteers
- 221 people
- Sponsor
- Turku University Hospital
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
The purpose of this pilot study is to use a pre surgical intervention model to evaluate the biologic effects of metformin in women with newly diagnosed early invasive breast cancer.
- Trial name
- NCT00930579
- Testing
- Metformin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Columbia University
Polycystic Ovary Syndrome
Pharmacogenetics of Metformin Action in PCOS
1. The polycystic ovary syndrome is the major cause of infertility in the United States. Metformin has been shown to increase frequency of ovulations in PCOS, and is used in clinical practice to treat infertility, but some women…
- Trial name
- NCT00703508
- Testing
- Metformin 500 mg tablet
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Virginia Commonwealth University
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes…
- Trial name
- NCT00700817
- Testing
- liraglutide, sitagliptin, metformin
- Where
- 166 sites in United States, Canada and 13 more
- Volunteers
- 665 people
- Sponsor
- Novo Nordisk A/S
Clinical Pharmacology
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
This is a randomized, open-label, crossover study to determine the effect of food when a combination tablet of SYR-322 and metformin hydrochloride ( hereinafter referred to as SYR-322-MET tablet) is orally administered under…
- Trial name
- NCT02276274
- Testing
- SYR-322-MET
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
- Trial name
- NCT01422876
- Testing
- high dose FDC, BI 10773 high dose
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,405 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Breast Tumors
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in…
- Trial name
- NCT02472353
- Testing
- Metformin, Doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT02496000
- Testing
- ORMD-0801
- Where
- 34 sites in United States
- Volunteers
- 188 people
- Sponsor
- Oramed, Ltd.
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital